Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Running, not enrolling
Conditions studied: Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
In brief
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
Key facts
- Study ID
- NCT04056247
- Run by
- OncoHost Ltd.
- People needed
- 10000
- Starts
- 2019-10-01
- Expected to finish
- 2029-10-01
- Last updated by the study team
- 2025-10-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provision of informed consent prior to any study-specific procedures.
- Male or female aged at least 18 years.
- ECOG PS - 0/1-2
- Normal hematologic, renal and liver function:
- Absolute neutrophil count higher than 1500/mm3
- Platelets count higher than 100,000/mm3
- haemoglobin higher than 9 g/dL
- Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min
- Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit.
- At least one measurable lesion in order to enable the assessment of the response (except for stage IIIb-d malignant melanoma patients).
You may not qualify if…
- Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug
- Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
Where it is running
- Birmingham VAHCS — Birmingham, Alabama, United States
- Mayo Clinic — Jacksonville, Florida, United States
- University of Miami — Miami, Florida, United States
- Florida Cancer Specialist and Research Institute — Orlando, Florida, United States
- Protean Biodiagnosics — Orlando, Florida, United States
- Northwest Community Healthcare — Rolling Meadows, Illinois, United States
- Helen Nassif Community Cancer Center — Cedar Rapids, Iowa, United States
- Rutgers Cancer Institute — New Brunswick, New Jersey, United States
- Roswell Park — Buffalo, New York, United States
- West Clinic — Germantown, Tennessee, United States
- Michael E. Debakey VA Medical Center — Houston, Texas, United States
- 151-Christus Health St. Michael — Texarkana, Texas, United States
- Asklepois — Gauting, Germany
- Thoraxklinik Heidelberg gGmbH — Heidelberg, Germany
- Haemek Medical Center — Afula, Israel
- Barzilai Medical Center — Ashkelon, Israel
- Soroka Medical Center — Beersheba, Israel
- Shamir Medical Center — Be’er Ya‘aqov, Israel
- Bnai Zion Medical Center — Haifa, Israel
- Rambam Medical Center — Haifa, Israel
- Hadassah Medcial Center — Jerusalem, Israel
- Meir medical center — Kfar Saba, Israel
- Rabin Medical Center — Petah Tikva, Israel
- Kaplan Medical Center — Rehovot, Israel
- Assuta Medical Cetner — Tel Aviv, Israel
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.